The ultimate goal of this research is to define the human cytolytic T lymphocyte (CTL) response to leukemia by utilizing purified and well-characterized antigens, cloned CTL lines, and monoclonal antibodies to functional T-cell subsets. In order to better understand the CTL response, it is necessary to define the antigens that trigger this response and to define the cell interactiona that regulate this response. Since CTLs appear in all cases studied to respond to integral membrane proteins (whether they be foreign MHC antigens or autologous MHC antigens in association with foreign antigens such as a virus), it has been difficult to define the antigens involved in CTL triggering. Initial studies in murine xenogeneic, allogeneic, and syngeneic CTL model systems demonstrate that H-2 and HLA antigens can be isolated from the cell surface and retain CTL stimulating activity. These results suggest that the antigenic requirements for the stimulation of human CTLs can be approached in a similar manner. The ability to obtain cloned CTL lines should allow one to define more precisely the specificity of CTLs. Thus, one can hope to determine what target antigens are recognized by monoclonal CTLs when triggered by well-defined antigens, i.e., purified MHC antigens or purified viral antigens plus MHC antigens inserted into artificial membranes or liposomes. The ability to obtain cloned helper T cells or suppressor T cells should also allow a more careful delineation of the cell-cell interactions that regulate the CTL response. These cloned functional T-cell lines may provide the appropriate reagents to raise antibodies to antigens specific for functional subsets of T cells. The availability of antibodies to human CTLs should subdivide the T-cell subset defined by OKT5 and OKT8 and allow a separation of CTLs from suppressor T cells. These new reagents may also allow us to isolate biochemically and define these cell surface antigens, possibly even resulting in the isolation and characterization of functional T-cell receptors. (LB)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA034129-08
Application #
3171888
Study Section
Immunobiology Study Section (IMB)
Project Start
1982-07-01
Project End
1991-05-31
Budget Start
1989-06-01
Budget End
1991-05-31
Support Year
8
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02115
Maziarz, R T; Groh, V; Prendergast, M et al. (1991) Non-MHC-restricted target-cell lysis by a CD4-CD8- TCR alpha beta T-cell line, as well as by TCR gamma delta T-cell lines, results from lymphokine-activated killing. Int J Cancer 48:142-7
Hahn, W C; Rosenstein, Y; Burakoff, S J et al. (1991) Interaction of CD2 with its ligand lymphocyte function-associated antigen-3 induces adenosine 3',5'-cyclic monophosphate production in T lymphocytes. J Immunol 147:14-21
Bierer, B E; Burakoff, S J (1991) T cell receptors: adhesion and signaling. Adv Cancer Res 56:49-76
Wolff, H L; Burakoff, S J; Bierer, B E (1990) Functional CD2 mutants unable to bind to, or be stimulated by, LFA-3. J Immunol 144:1215-20
Sen, J; Rosenberg, N; Burakoff, S J (1990) Expression and ontogeny of CD2 on murine B cells. J Immunol 144:2925-30
Bierer, B E; Bogart, R E; Burakoff, S J (1990) Partial deletions of the cytoplasmic domain of CD2 result in a partial defect in signal transduction. J Immunol 144:785-9
Sen, J; Arceci, R J; Jones, W et al. (1989) Expression and ontogeny of murine CD2. Eur J Immunol 19:1297-302
Bierer, B E; Burakoff, S J (1989) T-lymphocyte activation: the biology and function of CD2 and CD4. Immunol Rev 111:267-94
Jones, W K; Sen, J; Burakoff, S J (1989) Murine CD2: structure, expression, and recognition of human LFA-3. Year Immunol 6:95-111
Santos-Aguado, J; Crimmins, M A; Mentzer, S J et al. (1989) Alloreactivity studied with mutants of HLA-A2. Proc Natl Acad Sci U S A 86:8936-40

Showing the most recent 10 out of 41 publications